Quantcast

Latest Olanzapine Stories

2011-02-02 09:12:00

LONDON, February 2, 2011 /PRNewswire/ -- Thirteen US blockbusters will lose patent protection over the next two years, data from EvaluatePharma show, highlighting the challenges facing the pharmaceutical industry in the coming years. With the reporting season in full swing it is no wonder that several big pharmaceutical company chief executives have warned of tough times ahead. - Drugs worth $15.3bn face generic competition this year - "At risk" sales to more than double to...

475adc8e9acf5b0b636c6cdc4ca90bb2
2011-01-11 14:00:00

Eli Lilly and Co. will join forces with German drugmaker Boehringer Ingelheim to develop diabetes treatments, as the U.S. pharmaceutical company pushes to fill a looming revenue gap created by expiring patents for several key drugs. Lilly will pay Boehringer Ingelheim $387.4 million as part of a joint bid to develop and sell up to five drugs.  The two companies will split revenues from any approved drugs, not counting costs for making and selling the product.  Each drugmaker will...

2011-01-10 08:54:23

(Ivanhoe Newswire) -- Top-selling drugs, known as atypical antipsychotic medications, lack evidence that they'll actually be beneficial, according to a new study. Drugs in this class may cause serious effects such as weight gain, diabetes, and heart disease, along with costing Americans billions of dollars. "Because these drugs have safety issues, physicians should prescribe them only when they are sure patients will get substantial benefits," Randall Stafford, M.D., Ph.D., associate...

692a477b154ab04597e11f21e9246bcb
2011-01-07 08:45:00

Researchers from the Stanford University School of Medicine and the University of Chicago have found that many people currently using a specific type of antipsychotic medication are doing so for a condition that the drug has not yet been proven effective in treating. According to their findings, published online Friday in the journal Pharmacoepidemiology and Drug Safety, atypical antipsychotic medications were originally approved by the Food and Drug Administration (FDA) in 1989 for treating...

2010-11-12 13:09:15

Findings indicate two drugs of same class carry no difference in risk of mortality, a help for prescribing physicians The potential for harmful side effects associated with anti-psychotic medications for treating schizophrenia is a frustration for mental-health professionals who must balance this with the positive benefits of drugs. For example, the issue of the antipsychotic drug ziprasidone lengthening the QTc interval, a possible indicator of life-threatening heart arrhythmias, has...

2010-10-21 05:30:00

INDIANAPOLIS, Oct. 21 /PRNewswire-FirstCall/ -- Total revenue growth of 2 percent driven by higher demand in international markets Animal Health revenue increased 12 percent Q3 earnings per share grew to $1.18 (reported), or $ 1.21 (non-GAAP) Cost reduction initiatives continued to advance across business areas 2010 earnings per share guidance range raised to $4.55 - $4.65 (reported), or $4.65 - $4.75 (non-GAAP) Eli Lilly and Company (NYSE: LLY) today announced financial results for...

2010-09-10 17:38:00

INDIANAPOLIS, Sept. 10 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Court of Appeals for the Second Circuit has agreed with Lilly's position that a class should not have been certified in a pending third-party payor suit, in which unions and insurers who act as third-party payors alleged that they overpaid for Zyprexa prescriptions. The court also agreed with Lilly that plaintiffs' overpricing claims should not go forward. "We are very...

2010-08-25 08:00:00

WALTHAM, Mass., Aug. 25 /PRNewswire/ --Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the increased generic erosion of key drugs such as lamotrigine (GlaxoSmithKline's Lamictal, generics) and divalproex (Abbott/Sanofi-Aventis's Depakote/Abbott's Depakote ER, generics), combined with projected generic erosion of the atypical antipsychotic drug class will cause a precipitous $2.3 billion decline in the bipolar...

2010-08-05 12:00:00

WALTHAM, Mass., Aug. 5 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, after peaking at $6.3 billion in 2011, the schizophrenia drug market will decline to $5.2 billion in 2019, owing to the loss of patent protection for most atypical antipsychotics on the market. The Pharmacor 2010 findings from the topic entitled Schizophrenia reveal that the generic erosion of key agents -- most notably...

2010-07-22 05:30:00

INDIANAPOLIS, July 22 /PRNewswire-FirstCall/ -- Nine percent revenue growth driven by higher volume continues strong trend for the year. 21 percent of Q2 revenue invested in R&D to advance pipeline of nearly 70 potential new medicines in clinical development. Ongoing cost-containment efforts support double-digit growth in operating income. Q2 earnings per share grow to $1.22 (reported), or $1.24 (non-GAAP). 2010 earnings per share guidance range raised to $4.44 to $4.59 (reported),...


Word of the Day
jument
  • A beast of burden; also, a beast in general.
'Jument' ultimately comes from the Latin 'jugum,' yoke.
Related